Latest Repligen Corp (RGEN) Headlines Repligen
Post# of 44
Posted On: 03/13/2014 1:19:12 PM
Latest Repligen Corp (RGEN) Headlines
Repligen EPS plunges, misses
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The biotech said Q4 EPS fell nearly 67% to 10 cents, missing views by 4 cents. Revenue dipped 18.2% to $15.4 mil. Product gross margin widened to 55.3% from 39% in the year ago quarter. R&D expense fell 39.3%. Repligen (RGEN) sees '14 revenue of $54...
Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Repligen Corporation Shares Were Slammed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life-sciences company that...
Repligen Reports Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
- 2013 Product Revenue Growth of 13.5% -
Uptrend Call Working As Repligen Stock Rises 74.9% (RGEN)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 74.91% as of today's recent price of $14.92.
Repligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results
GlobeNewswire - Tue Feb 25, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year 2013 financial results on Thursday, March 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 9:00 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2013. In addition, the Company will provide financial guidance for its fiscal year 2014.
Repligen Has Returned 94.4% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Mon Feb 24, 9:13AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 94.40% as of today's recent price of $16.58.
Your Gadgets
by Patrick Buchana - All Africa Global Media - Thu Feb 20, 10:34PM CST
Gadget: Samsung Smart Gear
Repligen Has Returned 70.3% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Fri Feb 07, 11:07AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 7 months, Repligen has returned 70.34% as of today's recent price of $14.53.
Commit To Buy Repligen Corp. At $12.50, Earn 12.8% Annualized Using Options
StockOptionsChannel.com - Mon Feb 03, 11:38AM CST
Investors eyeing a purchase of Repligen Corp. shares, but cautious about paying the going market price of $14.68/share, might benefit from considering selling puts among the alternative strategies at their disposal.
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 25, 11:13AM CST
I don't know about you, but to me, between the J.P. Morgan Healthcare Conference two weeks ago and a flurry of earnings and trial data, it seems like an exceptionally furious start to the year for biotech stocks. This marks our third week in a row...
Repligen, Southwest Air, Evercore Stocks Hold Firm
at Investor's Business Daily - Fri Jan 24, 4:16PM CST
The past two sessions have been challenging for stock market bulls. When distribution days are rising and stocks are pulling back sharply, it's the right time to cut losses and prevent significant winners from transforming into losers. That said, a...
Shares of RGEN Up 64.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jan 24, 9:13AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 7 months, Repligen has returned 64.83% as of today's recent price of $14.06.
2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018
M2 - Fri Jan 24, 4:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/rbvt8k/epigenetics_drugs) has announced the addition of the "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018" report to their offering. "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018", on the epigenetics drugs and diagnostic technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report also provides analysis of the drugs market by the mechanism of its action namely, DNMT inhibitors and HDAC inhibitors. The report also discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year. The market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report. Competitive landscape and end user analysis for the product types is highlighted and the market players are profiled with attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. The global epigenetics drugs and diagnostic technologies market is segmented into the following categories: - Epigenetics Drugs Market, by Mechanism of Action - DNMT Inhibitors - Azacitidine (Vidaza) - Decitabine (Dacogen - HDAC Inhibitors - Vorinostat (Zolinza - Romidepsin (Istodax) - Epigenetics Diagnostic Technologies Market, by Types - DNA Methylation - Chromatin Immunoprecipitation (ChIP) Technology Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Epigenetics Drugs Market, By Mechanism Of Action 5 Epigenetics Diagnostic Technology Market, By Types 6 Global Epigenetics Technologies Market, By Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - 4SC - Acetylon Pharmaceuticals - Astex Pharmaceuticals - Celgene Corporation - Cellcentric - Celleron Therapeutics - Chroma Therapeutics - Eisai - Envivo Pharmaceuticals - Epigentek Group - Epizyme - Illumina - Mdxhealth - Merck & Company - Novartis International - Oncolys Biopharma - Pharmacyclics - Repligen Corporation - Spectrum Pharmaceuticals - Syndax Pharmaceuticals - Topotarge - Valirx For more information visit http://www.researchandmarkets.com/research/rb...tics_drugs
Why Repligen Corporation Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 3:24PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life sciences company that...
Repligen, Continuing Overhaul, Flips Rare Disease Drugs to BioMarin
Ben Fidler, Xconomy, The Motley Fool - Motley Fool - Tue Jan 21, 10:10AM CST
Waltham, MA-based Repligen decided a few years ago that it would be better off abandoning drug development and focusing instead on bioprocessing. Today it's cut a deal to shed some of its remaining therapeutic baggage. Repligen has licensed its...
Repligen EPS plunges, misses
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The biotech said Q4 EPS fell nearly 67% to 10 cents, missing views by 4 cents. Revenue dipped 18.2% to $15.4 mil. Product gross margin widened to 55.3% from 39% in the year ago quarter. R&D expense fell 39.3%. Repligen (RGEN) sees '14 revenue of $54...
Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Repligen Corporation Shares Were Slammed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life-sciences company that...
Repligen Reports Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
- 2013 Product Revenue Growth of 13.5% -
Uptrend Call Working As Repligen Stock Rises 74.9% (RGEN)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 74.91% as of today's recent price of $14.92.
Repligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results
GlobeNewswire - Tue Feb 25, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year 2013 financial results on Thursday, March 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 9:00 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2013. In addition, the Company will provide financial guidance for its fiscal year 2014.
Repligen Has Returned 94.4% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Mon Feb 24, 9:13AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 94.40% as of today's recent price of $16.58.
Your Gadgets
by Patrick Buchana - All Africa Global Media - Thu Feb 20, 10:34PM CST
Gadget: Samsung Smart Gear
Repligen Has Returned 70.3% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Fri Feb 07, 11:07AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 7 months, Repligen has returned 70.34% as of today's recent price of $14.53.
Commit To Buy Repligen Corp. At $12.50, Earn 12.8% Annualized Using Options
StockOptionsChannel.com - Mon Feb 03, 11:38AM CST
Investors eyeing a purchase of Repligen Corp. shares, but cautious about paying the going market price of $14.68/share, might benefit from considering selling puts among the alternative strategies at their disposal.
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 25, 11:13AM CST
I don't know about you, but to me, between the J.P. Morgan Healthcare Conference two weeks ago and a flurry of earnings and trial data, it seems like an exceptionally furious start to the year for biotech stocks. This marks our third week in a row...
Repligen, Southwest Air, Evercore Stocks Hold Firm
at Investor's Business Daily - Fri Jan 24, 4:16PM CST
The past two sessions have been challenging for stock market bulls. When distribution days are rising and stocks are pulling back sharply, it's the right time to cut losses and prevent significant winners from transforming into losers. That said, a...
Shares of RGEN Up 64.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jan 24, 9:13AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 7 months, Repligen has returned 64.83% as of today's recent price of $14.06.
2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018
M2 - Fri Jan 24, 4:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/rbvt8k/epigenetics_drugs) has announced the addition of the "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018" report to their offering. "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018", on the epigenetics drugs and diagnostic technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report also provides analysis of the drugs market by the mechanism of its action namely, DNMT inhibitors and HDAC inhibitors. The report also discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year. The market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report. Competitive landscape and end user analysis for the product types is highlighted and the market players are profiled with attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. The global epigenetics drugs and diagnostic technologies market is segmented into the following categories: - Epigenetics Drugs Market, by Mechanism of Action - DNMT Inhibitors - Azacitidine (Vidaza) - Decitabine (Dacogen - HDAC Inhibitors - Vorinostat (Zolinza - Romidepsin (Istodax) - Epigenetics Diagnostic Technologies Market, by Types - DNA Methylation - Chromatin Immunoprecipitation (ChIP) Technology Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Epigenetics Drugs Market, By Mechanism Of Action 5 Epigenetics Diagnostic Technology Market, By Types 6 Global Epigenetics Technologies Market, By Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - 4SC - Acetylon Pharmaceuticals - Astex Pharmaceuticals - Celgene Corporation - Cellcentric - Celleron Therapeutics - Chroma Therapeutics - Eisai - Envivo Pharmaceuticals - Epigentek Group - Epizyme - Illumina - Mdxhealth - Merck & Company - Novartis International - Oncolys Biopharma - Pharmacyclics - Repligen Corporation - Spectrum Pharmaceuticals - Syndax Pharmaceuticals - Topotarge - Valirx For more information visit http://www.researchandmarkets.com/research/rb...tics_drugs
Why Repligen Corporation Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 3:24PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life sciences company that...
Repligen, Continuing Overhaul, Flips Rare Disease Drugs to BioMarin
Ben Fidler, Xconomy, The Motley Fool - Motley Fool - Tue Jan 21, 10:10AM CST
Waltham, MA-based Repligen decided a few years ago that it would be better off abandoning drug development and focusing instead on bioprocessing. Today it's cut a deal to shed some of its remaining therapeutic baggage. Repligen has licensed its...
(0)
(0)